Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib

Lung Cancer

Volumn 57, Issue 2, 2007, Pages 213-221

  Chiu, Chao Hua ^a,b   Shih, Yu Ning ^a,b   Tsai, Chun Ming ^a,b   Liou, Jia Ling ^a   Chen, Yuh Min ^a,b   Perng, Reury Perng ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Carbohydrate antigen 125; Carbohydrate antigen 19 9; Carcinoembryonic antigen; Clinical benefit; Gefitinib; Non small cell lung cancer

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEFITINIB; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34447268726     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.02.016     Document Type: Article

References (18)

1. Erasmus J.J., Gladish G.W., Broemeling L., et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 21 (2003) 2574-2582
2. Georgoulias V., Ardavanis A., Agelidou A., et al. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J Clin Oncol 22 (2004) 2602-2609
3. Kelloff G.J., Bast R.C., Coffey D.S., et al. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update. Clin Cancer Res 10 (2004) 3881-3884
4. Al-Sarraf M., Baker L., Talley R.W., Kithier K., and Vaitkevicius V.K. The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. Cancer 44 (1979) 1222-1225
5. Bridgewater J.A., Nelstrop A.E., Rustin G.J., et al. Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol 17 (1999) 501-508
6. Rustin G.J., Nelstrop A.E., Bentzen S.M., Bond S.J., and McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 18 (2000) 1733-1739
7. Taylor J.M., Griffith K.A., and Sandler H.M. Definitions of biochemical failure in prostate cancer following radiation therapy. Int J Radiat Oncol Biol Phys 50 (2001) 1212-1219
8. Bartlett N.L., Freiha F.S., and Torti F.M. Serum markers in germ cell neoplasms. Hematol Oncol Clin North Am 5 (1991) 1245-1260
9. Wang W.S., Lin J.K., Lin T.C., et al. Carcinoembryonic antigen in monitoring of response to systemic chemotherapy in patients with metastatic colorectal cancer. Int J Colorectal Dis 16 (2001) 96-101
10. Spiridonidis C.H., Laufman L.R., Stydnicki K.A., et al. Decline of posttreatment tumor marker levels after therapy of non-small cell lung cancer. A useful outcome predictor. Cancer. 75 (1995) 1586-1593
11. Chiu C.H., Tsai C.M., Chen Y.M., Chiang S.C., Liou J.L., and Perng R.P. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 47 (2005) 129-138
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
13. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
14. Chou T.Y., Chiu C.H., Li L.H., et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11 (2005) 3750-3757
15. Miller V.A., Kris M.G., Shan N., et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 1103-1109
16. Mitsudomi T., Kosaka T., Endoh H., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
17. Bubley G.J., Carducci M., Dahut W., et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17 (1999) 3461-3467
18. Rustin G.J., Quinn M., Thigpen T., et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96 (2004) 487-488